CDK4 and neoplasm: Therefore, there is a need for non-invasive tools to quantify CDK4/6 target engagement to ensure that CDK4/6 inhibitors reach concentrations in the brain sufficient to elicit pharmacological effects in tumor tissues and to provide information on response to treatment in real time.